Drug intelligence / Profile preview

IGN001

Development stage: Unknown
Lead developer: ImmunGene
Modality: Ligand-Fc Fusions → Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

IGN001 is an antibody-interferon fusion protein developed by ImmunGene, Inc., designed to treat various cancers by leveraging antibody-directed delivery of interferon to enhance antitumor activity through immune-mediated cytotoxicity. It belongs to a series of similar candidates (IGN002, IGN003) that were outlicensed and later regained by ImmunGene in 2013 from Valor Biotherapeutics. Limited public data exists on its specific mechanism, targets, clinical trials, or current status, suggesting it is an early preclinical or development-stage asset focused on oncology.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on IGN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGN001.

Explore the full profile